Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Achievement of pathologic complete response is important prognosticator to predict long term
outcome in triple negative cancer. The efficacy of adding 4 cycles of cisplatin (CDDP4) is to
be investigated whether addtional pathologic complete response is achieved for those triple
negative breast cancer patients who recieved 4 cycles of adriamycin with
cyclophosphamide(AC4) but did not reach clinical complete response during the course of
neoadjuvant therapy.